Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
1.
Angew Chem Int Ed Engl ; 63(1): e202313336, 2024 Jan 02.
Artículo en Inglés | MEDLINE | ID: mdl-37983653

RESUMEN

The precise control of the regioselectivity in the transition metal-catalyzed migratory hydrofunctionalization of alkenes remains a big challenge. With a transient ketimine directing group, the nickel-catalyzed migratory ß-selective hydroarylation and hydroalkenylation of alkenyl ketones has been realized with aryl boronic acids using alkyl halide as the mild hydride source for the first time. The key to this success is the use of a diphosphine ligand, which is capable of the generation of a Ni(II)-H species in the presence of alkyl bromide, and enabling the efficient migratory insertion of alkene into Ni(II)-H species and the sequent rapid chain walking process. The present approach diminishes organosilanes reductant, tolerates a wide array of complex functionalities with excellent regioselective control. Moreover, this catalytic system could also be applied to the migratory hydroarylation of alkenyl azahetereoarenes, thus providing a general approach for the preparation of 1,2-aryl heteroaryl motifs with wide potential applications in pharmaceutical discovery.

2.
J Int Med Res ; 51(10): 3000605231206958, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37899573

RESUMEN

Duodenal stenosis caused by upper tract urothelial carcinoma (UTUC) is rare. A 70-year-old male patient was diagnosed with a UTUC invading the duodenum 3 months before admission. Owing to duodenal stenosis, enteral nutrition was necessary. We performed pancreaticoduodenectomy with right nephroureterectomy and right hemicolectomy using a multi-disciplinary approach. Postoperative pathology revealed a UTUC invading the right kidney, duodenum, pancreas, and transverse colon. The patient underwent chemotherapy and immunotherapy after surgery, which improved his quality of life.


Asunto(s)
Carcinoma de Células Transicionales , Neoplasias de la Vejiga Urinaria , Masculino , Humanos , Anciano , Carcinoma de Células Transicionales/patología , Neoplasias de la Vejiga Urinaria/cirugía , Calidad de Vida , Nefroureterectomía
3.
Am J Mens Health ; 17(3): 15579883231183770, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37381630

RESUMEN

To evaluate the clinical efficacy of pelvic floor low-frequency electrical stimulation combined with anus lifting training in the treatment of urinary incontinence after radical prostatectomy in a Chinese cohort. Fifty-five patients with urinary incontinence after radical prostatectomy were randomly divided into treatment group and control group. Patients in control group received only anus lifting training therapy, while treatment group combined with pelvic floor low-frequency electrical stimulation. The urinary control including urinary incontinence questionnaire (ICI-Q-SF), urinary incontinence quality of life (I-QOL), visual analogue scale (VAS), and pelvic floor muscle strength assessment (Glazer) of the two groups of patients before treatment and every week was recorded for statistical analysis. There was a statistically significant difference between treatment group and control group in the urinary control curve. The scores of ICI-Q-SF, I-QOL, VAS, and Glazer in the treatment group after 2 weeks were statistically different from those before treatment, and effects were accumulating with the extension of treatment time. Compared with the control group, the scores of treatment group in the 2 to 10 weeks improved more significantly. Especially, in the sixth week, total effective rate of treatment group was significantly better than that of control group (74.07% [20/27], 35.71% [10/28], p < .05). The difference between two groups gradually narrowed after 10 weeks and no significant difference after 10 weeks of treatment between two groups. Pelvic floor low-frequency electrical stimulation combined with anus lifting training after radical prostatectomy can significantly shorten the recovery time of urinary incontinence in patients after radical prostatectomy.


Asunto(s)
Calidad de Vida , Incontinencia Urinaria , Masculino , Humanos , Canal Anal , Pueblos del Este de Asia , Elevación , Prostatectomía/efectos adversos , Incontinencia Urinaria/etiología , Incontinencia Urinaria/terapia , Estimulación Eléctrica
4.
Perfusion ; 38(2): 228-235, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-34617860

RESUMEN

PURPOSE: In this article, we aimed to elaborate on perioperative and complication management in treatment of pheochromocytoma crisis with extracorporeal membrane oxygenation (ECMO). MATERIAL AND METHODS: We report a case of relatively rare grant paraganglioma-induced pheochromocytoma crisis leading to severe circulatory failure, treated with venoarterial extracorporeal membrane oxygenation (V-A ECMO) as a bridge to curative adrenalectomy. Weaning of ECMO was followed by successful surgical removal of the tumor, and patient survival. However, distal ischemia of the cannulated leg occurred during ECMO operation, which eventually led to amputation. In addition, the patient developed new cerebral infarction and left hemiplegia, half a month after paraganglioma resection. CONCLUSIONS: We believe that patients with pheochromocytoma crisis, who cannot maintain blood circulation, are eligible for V-A ECMO treatment. Moreover, care should be taken to prevent thrombosis and individualized and precise blood pressure management targets. Early detection and treatment of thrombosis is imperative to long-term prognosis of patients with ECMO.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales , Oxigenación por Membrana Extracorpórea , Paraganglioma , Feocromocitoma , Trombosis , Humanos , Feocromocitoma/complicaciones , Feocromocitoma/cirugía , Neoplasias de las Glándulas Suprarrenales/complicaciones , Neoplasias de las Glándulas Suprarrenales/cirugía , Paraganglioma/complicaciones , Estudios Retrospectivos
5.
Bioengineered ; 13(3): 5373-5385, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-35184651

RESUMEN

Androgen deprivation therapy is currently the main therapeutic strategy for the treatment of advanced metastatic prostate cancer (ADPC). However, the tumor type in ADPC patients transforms into castration-resistant prostate cancer (CRPC) after 18-24 months of treatments, the underlying mechanism of which remains unclear. The present study aimed to investigate the potential pathological mechanism of the conversion from ADPC to CRPC by exploring the function of lung cancer metastasis-related protein 1 (LCMR1). We found that LCMR1 and glucocorticoid receptor α (GRα) were highly expressed in CRPC tissues, compared to ADPC tissues, and were accompanied by high concentrations of inflammatory factors. Knocking down LCMR1 or GRα in CRPC cells led to inhibition of metastasis and proliferation and induction of apoptosis. The expression of HSP90 and IL-6 was upregulated and that of androgen receptor was downregulated by knocking down LCMR1 or GRα in CRPC cells. Luciferase assay results indicated that the transcription of GRα was promoted by the LCMR1 promoter. The growth rate of CRPC cells in vivo was greatly decreased by knocking down LCMR1 or GRα. Lastly, CRPC cell sensitivity to enzalutamide treatment was found significantly enhanced by the knockdown of LCMR1. Taken together, LCMR1 might regulate the conversion of ADPC to CRPC by activating the GRα signaling pathway.


Asunto(s)
Neoplasias Pulmonares , Complejo Mediador/metabolismo , Neoplasias de la Próstata Resistentes a la Castración , Antagonistas de Andrógenos/uso terapéutico , Línea Celular Tumoral , Proliferación Celular/genética , Humanos , Neoplasias Pulmonares/metabolismo , Masculino , Neoplasias de la Próstata Resistentes a la Castración/tratamiento farmacológico , Neoplasias de la Próstata Resistentes a la Castración/genética , Neoplasias de la Próstata Resistentes a la Castración/metabolismo , Receptores de Glucocorticoides , Transducción de Señal
6.
Front Mol Biosci ; 8: 585000, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34926570

RESUMEN

Background: Kidney renal clear cell carcinoma (KIRC) has become one of the most prevalent malignancies worldwide and remains a crucial cause of cancer-related morbidity and mortality. Aberrant activation of the JAK/STAT pathway acts as an important role in KIRC. The suppressor of cytokine signaling (SOCS) family members are the key negative regulators of the JAK/STAT pathway. SOCS family members have been verified to act as significant roles in regulating cellular responses to many cytokines and growth factors. However, whether the expression levels of SOCS affect the prognosis of patients with KIRC is still elusive. Methods: We first evaluated the expression of SOCS family genes in KIRC and determined the correlation between SOCS expression and different clinicopathological features. Then, we analyzed the genetic alterations, potential functions, transcription factor targets, and immune infiltration of SOCS family members based on the information available on public databases. Finally, we assessed the prognostic value of differentially expressed SOCS family members. Results: The expression levels of SOCS2, SOCS4, SOCS6, SOCS7, and CISH were downregulated in KIRC, and all SOCS genes were associated with clinicopathological features of patients with KIRC. SOCS family members have been predominantly related to protein binding, signaling adaptor activity, and JAK/STAT cascade. We found that STAT3, STAT6, and IRF1 are the key transcription factors that may be participated in the regulation of SOCS. We also found an association between the expression levels of SOCS and the immune infiltrates of KIRC. Finally, we have illuminated that SOCS1 and SOCS3 are risky genes, whereas SOCS2, SOCS4, SOCS6, SOCS7, and CISH are some of the protective genes for patients with KIRC; based on these, we have created a KIRC prognostic index for predicting the prognosis of patients of KIRC. Conclusion: Our study may contribute to further understanding the functions of SOCS genes in KIRC, which may help clinicians in selecting the appropriate drugs and predicting the outcomes for patients with KIRC.

7.
Cancer Invest ; 39(10): 908-913, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34569904

RESUMEN

The present study reports the clinical data of a patient with pheochromocytoma who developed acute non-cardiac pulmonary edema. The patient has already been followed for 2 years after the initial surgery. Based on the case of our patient, and after the review of existing literature, we find that cases of patients who present dyspnea, shock and the lung changes of interstitial without according to respiratory common diseases tend to perform abdominal computed tomography (CT) to exclude pheochromocytoma. In addition, after receiving symptomatic treatment in acute left heart failure and pulmonary edema patients, having the poor effect, we have to consider the diagnosis of pheochromocytoma.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales/complicaciones , Feocromocitoma/complicaciones , Edema Pulmonar/etiología , Enfermedad Aguda , Humanos , Masculino , Persona de Mediana Edad , Tomografía Computarizada por Rayos X
8.
Front Mol Biosci ; 8: 689037, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34124165

RESUMEN

Background: Kidney renal clear cell carcinoma (KIRC) has the highest incidence rate in renal cell carcinoma (RCC). Although bioinformatics is widely used in cancer, few reliable biomarkers of KIRC have been found. Therefore, continued efforts are required to elucidate the potential mechanism of the biogenesis and progression of KIRC. Methods: We evaluated the expression of tumor necrosis factor (TNF) family genes in KIRC, and constructed a prognostic signature. We validated the signature by another database and explored the relationship between the signature and progression of KIRC. We assessed the prognostic value, immune infiltration, and tumor mutation burden (TMB) of the signature in KIRC. Results: We selected four key genes (TNFSF14, TNFRSF19, TNFRSF21, and EDA) to construct the TNF-related signature. We divided the KIRC patients into high- and low-risk groups based on the signature. Patients with higher risk scores had shorter overall survival and worse prognosis. With another database, we validated the value of the signature. The signature was considered as an independent risk factor. A higher level of risk score was relevant to higher level of immune infiltration, especially T regulatory cells, CD8+ T cells, and macrophages. The signature was also associated with TMB scores, and it may have an effect on assessing the efficacy of immunotherapy. Conclusion: This is the first TNF-family-related signature of KIRC and we demonstrated its effectiveness. It played a significant role in predicting the prognosis of patients with KIRC. It also has the potential to become a powerful tool in guiding the immunotherapy of KIRC patients in clinical practice.

9.
Int J Immunopathol Pharmacol ; 34: 2058738420925720, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32490707

RESUMEN

We report on a 31-year-old male patient with non-invasive papillary urothelial carcinoma, low grade of the renal pelvis disguised as xanthogranulomatous pyelonephritis. The only symptom of the patient was lower back pain. The initial renal-enhanced computed tomography, magnetic resonance imaging and contrast-enhanced ultrasonography showed that the right kidney had a benign lesion and this inflammatory lesion might be xanthogranulomatous pyelonephritis. A percutaneous renal biopsy was performed and histopathologic examination revealed a xanthogranulomatous pyelonephritis. Initially, we diagnosed it as xanthogranulomatous pyelonephritis and treated it with antibiotics. One and a half years later, the patient suffered from back pain again. The lesion increased significantly and a right renal pelvic lesion with retroperitoneal lymphadenopathy was considered a malignant lesion on computed tomography scan. Therefore, radical resection of right renal pelvis carcinoma was performed under retroperitoneal laparoscopy. Intraoperative frozen section was reported as right renal urothelial carcinoma with no metastasis in renal hilar lymph node. Postoperative histopathologic examination revealed non-invasive papillary urothelial carcinoma, low grade of renal pelvis.


Asunto(s)
Carcinoma Papilar/cirugía , Neoplasias Renales/cirugía , Pelvis Renal/cirugía , Pielonefritis Xantogranulomatosa/diagnóstico , Urotelio/patología , Adulto , Carcinoma Papilar/diagnóstico por imagen , Carcinoma Papilar/patología , Diagnóstico Diferencial , Humanos , Neoplasias Renales/diagnóstico por imagen , Neoplasias Renales/patología , Pelvis Renal/diagnóstico por imagen , Pelvis Renal/patología , Laparoscopía , Dolor de la Región Lumbar/etiología , Linfadenopatía/patología , Imagen por Resonancia Magnética , Masculino , Pielonefritis Xantogranulomatosa/patología , Tomografía Computarizada por Rayos X , Ultrasonografía
10.
Int J Immunopathol Pharmacol ; 34: 2058738420931619, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32567409

RESUMEN

We presented the clinical data of one patient with renal cell carcinoma associated with idiopathic thrombocytopenic purpura in this case report. We reported a 56-year-old man who presented with petechiae and ecchymoses. Laboratory studies showed the platelet count of 2 × 109/L and an abdominal computed tomography (CT) scan revealed tumors in the right renal. There were purpura on the legs and cough without abdominal pain and melena at this time. Idiopathic thrombocytopenic purpura was diagnosed according to the clinical symptoms and laboratory test. The patient received radical nephrectomy for renal carcinoma, and his idiopathic thrombocytopenic purpura was cured after the surgery. Pathological biopsy confirmed it was renal clear cell carcinoma. The patient has been followed up for more than 3 months after surgery, and the ecchymoses had not been recurred and the patient's thrombocytopenia was recovered. Idiopathic thrombocytopenic purpura associated with kidney cancer is rare. The patient in this case report was treated with radical nephrectomy, and the effectiveness of idiopathic thrombocytopenic purpura was satisfactory.


Asunto(s)
Carcinoma de Células Renales/complicaciones , Neoplasias Renales/complicaciones , Púrpura Trombocitopénica Idiopática/complicaciones , Biopsia , Médula Ósea/patología , Carcinoma de Células Renales/cirugía , Humanos , Neoplasias Renales/cirugía , Masculino , Persona de Mediana Edad , Nefrectomía , Púrpura Trombocitopénica Idiopática/tratamiento farmacológico , Tomografía Computarizada por Rayos X
11.
Cancer Manag Res ; 12: 3673-3689, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32547204

RESUMEN

Bladder cancer (BCa) is the 10th most prevalent malignancy worldwide and remains a crucial cause of cancer-related morbidity and mortality. Circular RNAs (circRNAs), a large class of endogenous non-coding RNAs, contain unique covalent closed structures and their biogenesis and turnover are regulated by multiple factors. Recently, multiple circRNAs have been found to serve as important factors in several biological processes such as tumorigenesis. An increasing amount of research discovered that circRNAs are dysregulated in multiple cancer tissues compared with matched normal tissues, especially in BCa, indicating that circRNAs can act as biomarkers for the diagnosis and prognosis of BCa. In this review, we focus on the biogenesis, properties, turnover, and functions of circRNAs, summarizing their potential functions and clinical implications in BCa.

12.
Kaohsiung J Med Sci ; 36(9): 712-720, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32436368

RESUMEN

To explore the mechanism of microRNA-155 (miR-155) deficiency, protecting against experimental autoimmune prostatitis (EAP) in a toll-like receptor 4 (TLR4)-dependent manner. After wild-type (WT) and miR-155-/- mice were injected with complete Freund's adjuvant and prostate antigen to establish EAP model, half were randomly selected for injection with lipopolysaccharide (LPS, a TLR4 ligand). The following experiments were then performed: von Frey filaments, hematoxylin-eosin (HE) staining, real time quantitative polymerase chain reaction (qRT-PCR), Western blotting, and enzyme-linked immunosorbent assay (ELISA). And the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and the level of Malondialdehyde (MDA) were detected by corresponding kits.miR-155-/- mice with prostatitis exhibited the attenuated pelvic tactile allodynia/hyperalgesia and the suppressed TLR4/nuclear factor-kappa B (NF-κB) pathway as compared with the WT mice with prostatitis. In addition, LPS enhanced the upregulation of miR-155 and the activation of the TLR4/NF-κB pathway in the prostatic tissues of WT mice with EAP. Furthermore, prostatitis mice had aggravated inflammation scores accompanying the increased interleukin (IL)-1ß, tumor necrosis factor-α, IL-6, interferon-γ, IL-12, and MDA in prostatic tissues with the decreased IL-10, SOD and GSH-Px, and the unaltered IL-4. Compared with the mice from the WT + EAP group and the miR-155-/- + EAP + LPS group, mice from the miR-155-/- + EAP group had decreased inflammation and oxidative stress. miR-155 deficiency ameliorated pelvic tactile allodynia/hyperalgesia in EAP mice and improved inflammation and oxidative stress in prostatic tissues in a TLR4-dependent manner involving NF-κB activation, thereby exerting a therapeutic effect in chronic prostatitis treatment.


Asunto(s)
Enfermedades Autoinmunes/genética , Hiperalgesia/genética , MicroARNs/genética , FN-kappa B/genética , Prostatitis/genética , Receptor Toll-Like 4/genética , Animales , Enfermedades Autoinmunes/inducido químicamente , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/prevención & control , Modelos Animales de Enfermedad , Adyuvante de Freund/administración & dosificación , Regulación de la Expresión Génica , Glutatión Peroxidasa/genética , Glutatión Peroxidasa/inmunología , Hiperalgesia/inducido químicamente , Hiperalgesia/inmunología , Hiperalgesia/prevención & control , Interferón gamma/genética , Interferón gamma/inmunología , Interleucina-12/genética , Interleucina-12/inmunología , Interleucina-1beta/genética , Interleucina-1beta/inmunología , Interleucina-6/genética , Interleucina-6/inmunología , Lipopolisacáridos/farmacología , Masculino , Malondialdehído/inmunología , Malondialdehído/metabolismo , Ratones , Ratones Noqueados , MicroARNs/inmunología , FN-kappa B/inmunología , Estrés Oxidativo , Antígeno Prostático Específico/administración & dosificación , Prostatitis/inducido químicamente , Prostatitis/inmunología , Prostatitis/prevención & control , Transducción de Señal , Superóxido Dismutasa/genética , Superóxido Dismutasa/inmunología , Receptor Toll-Like 4/inmunología , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/inmunología
13.
Aging (Albany NY) ; 12(7): 6352-6369, 2020 04 13.
Artículo en Inglés | MEDLINE | ID: mdl-32283544

RESUMEN

Family with sequence similarity 46 member C (FAM46C) is a non-canonical poly(A) polymerase that is associated with tumorigenesis. However, its role in prostate cancer development is not fully understood. Herein, we determined expression pattern of FAM46C in prostate cancer and further identified its effect on the tumorigenesis and chemosensitivity. FAM46C expression was decreased in prostate cancer tissues and cell lines compared with corresponding controls. FAM46C expression was significantly associated with the Gleason score, tumor size and overall survival. FAM46C knockdown in 22RV1 and DU145 cells significantly inhibited apoptosis and promoted cell proliferation and cell cycle progression as well as activation of AKT. FAM46C overexpression had an inverse effect in DU145 cells and inhibited tumor growth in vivo. FAM46C inhibited cell proliferation and cell cycle progression and induced apoptosis via the PTEN/AKT signaling pathway. FAM46C promoted PTEN expression through inhibiting PTEN ubiquitination. The prostate cancer cells and patient-derived xenograft (PDX) mice with high-FAM46C-expressing demonstrated an enhanced chemosensitivity to docetaxel. These findings suggest that FAM46C control cell proliferation, cell cycle and apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity of prostate cancer. Modulation of their levels may offer a new approach for improving anti-tumor efficacy for chemotherapeutic agents in prostate cancer.


Asunto(s)
Docetaxel/farmacología , Nucleotidiltransferasas/metabolismo , Fosfohidrolasa PTEN/metabolismo , Polinucleotido Adenililtransferasa/metabolismo , Neoplasias de la Próstata , Animales , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Carcinogénesis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica , Humanos , Masculino , Ratones , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Transducción de Señal/efectos de los fármacos , Ensayos Antitumor por Modelo de Xenoinjerto
14.
Medicine (Baltimore) ; 99(15): e19760, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32282738

RESUMEN

BACKGROUND: In recent years, metastatic castration-resistant prostate cancer (MCRPC) and studies related to MCRPC have drawn global attention. The main objective of this bibliometric study was to provide an overview of MCRPC, explore clusters and trends in research and investigate the future direction of MCRPC research. METHODS: A total of 4089 publications published between 1979 and 2018 were retrieved from the Web of Science (WoS) Core Collection database. Different aspects of MCRPC research, including the countries/territories, institutions, journals, authors, research areas, funding agencies and author keywords, were analyzed. RESULTS: The number of annual MCRPC publications increased rapidly after 2010. American researchers played a vital role in this increase, as they published the most publications. The most productive institution was Memorial Sloan Kettering Cancer Center. De Bono, JS (the United Kingdom [UK]) and Scher, HI (the United States of America [USA]) were the two most productive authors. The National Institutes of Health (NIH) funded the largest number of published papers. Analyses of keywords suggested that therapies (abiraterone, enzalutamide, etc.) would attract global attention after US Food and Drug Administration (FDA) approval. CONCLUSIONS: Developed countries, especially the USA, were the leading nations for MCRPC research because of their abundant funding and frequent international collaborations. Therapy was one of the most vital aspects of MCRPC research. Therapies targeting DNA repair or the androgen receptor (AR) signing pathway and new therapies especially prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) would be the next focus of MCRPC research.


Asunto(s)
Neoplasias de la Próstata Resistentes a la Castración/tratamiento farmacológico , Neoplasias de la Próstata Resistentes a la Castración/secundario , Publicaciones/normas , United States Food and Drug Administration/organización & administración , Androstenos/uso terapéutico , Benzamidas , Bibliometría , Neoplasias Óseas/secundario , Reparación del ADN/efectos de los fármacos , Humanos , Masculino , Metástasis de la Neoplasia , Nitrilos , Feniltiohidantoína/análogos & derivados , Feniltiohidantoína/uso terapéutico , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata Resistentes a la Castración/patología , Publicaciones/tendencias , Receptores Androgénicos/efectos de los fármacos , Receptores Androgénicos/genética , Reino Unido/epidemiología , Estados Unidos/epidemiología
15.
Int J Surg ; 75: 74-79, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31926329

RESUMEN

BACKGROUND: The purpose of this bibliometric analysis was to identify and assess the 100 most-cited articles (T100 articles) on urological surgery. METHODS: The Web of Science (WoS) Core Collection database was used to investigate the T100 articles in the field of urological surgery. Different aspects of the T100 articles, including the countries, journals, authors, and topics, were analyzed. RESULTS: The number of citations of T100 articles published between 1989 and 2016 ranged from 334 to 2189. The T100 articles originated from 28 countries, with more than half originating from the USA (n = 80). Professor Bill-Axelson A from Uppsala University Hospital published the largest number of T100 articles as the first author (4) and as a coauthor (1). The Memorial Sloan Kettering Cancer Center from the USA is the top institution with the most T100 articles in the field of urological surgery. The special journal Journal of Urology published 41 of the T100 articles, which had a total of 19780 citations. CONCLUSIONS: Our study analyzed the 100 most-cited articles in the field of urological surgery. The USA is the dominant country in terms of the number of T100 articles, scientists and institutions. Surgery related to urological cancer has garnered the most academic attention, especially prostate cancer and renal cancer.


Asunto(s)
Bibliometría , Publicaciones Periódicas como Asunto/estadística & datos numéricos , Procedimientos Quirúrgicos Urológicos , Humanos , Especialidades Quirúrgicas
16.
Am J Transl Res ; 11(3): 1255-1269, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30972160

RESUMEN

Prostate cancer (PCa) is a leading cause of cancer-related deaths among men. The anthracycline doxorubicin (DOX) is used for the treatment of this disease, but its considerable side effects and non-selectivity are major drawbacks. Simvastatin (Sim), a lipid-lowering agent, holds great promise as a cancer therapeutic, and thus could be used in combination with DOX. Targeted drug-loaded nano-carriers with antibodies for receptors that are overexpressed on tumor cells are promising strategies for decreasing toxicity to normal tissues and enhancing the efficacy of chemotherapies in cancer treatment. Specifically, human epidermal growth factor 2 is overexpressed and constitutively activated in the PC-3 cell line. Within this context, we designed a co-delivery system coated with Herceptin for PCa, performed physicochemical characterizations, and tested the formulations for cytotoxicity and uptake. The targeted liposomes had a mean particle size of 134 nm, and the drug encapsulation efficiency of both Sim and DOX were greater than 80%. We discovered that the drug combination led to the strong inhibition of PCa both in vitro and in vivo, with inhibitory rates of tumor volumes corresponding to 80.36% and 68.77% of Herceptin-coated liposomes and non-targeted liposomes, respectively. We also found that the anti-tumor mechanisms of the DOX and Sim combination were possibly attributed to synergistic anti-angiogenesis. These results reveal that Herceptin-conjugated liposomes co-loaded with DOX and Sim are a potential novel therapeutic strategy for overcoming PCa.

17.
Medicine (Baltimore) ; 97(28): e11379, 2018 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-29995779

RESUMEN

BACKGROUND: The relationship between male pattern baldness and incidence of prostate cancer remains inconclusive. Hence, we performed the present meta-analysis based on all eligible cohort and case-control studies. METHODS: A comprehensive literature search was performed in October 2017 based on PubMed and Web of Science databases. Pooled relative risk (RR) and its 95% confidence interval (95% CI) was calculated with a DerSimonian and Laird random-effects model. RESULTS: A total of 15 studies were included in this meta-analysis. Overall, no statistically significant association between baldness (any pattern) and prostate cancer risk was identified (RR: 1.03, 95% CI 0.96-1.11). There was obvious heterogeneity across included studies (P < .078 for heterogeneity, I = 36.4%). When subgroup analysis by types of baldness, a statistically significant association was observed for vertex baldness (RR 1.24, 95% CI 1.05-1.46) but not for other types of baldness. CONCLUSION: Individuals with vertex baldness may have an increased risk of prostate cancer. Given the obvious heterogeneity and null results in overall analysis and most of subgroup analyses, further large well-designed prospective cohort studies are warranted to confirm our preliminary findings.


Asunto(s)
Alopecia/complicaciones , Neoplasias de la Próstata/complicaciones , Humanos , Incidencia , Masculino , Neoplasias de la Próstata/epidemiología , Factores de Riesgo
18.
Drug Metab Dispos ; 45(1): 109-117, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-27821436

RESUMEN

In recent years, finding effective biomarkers for identifying early stage cancer and predicating prognosis is crucial for renal cell carcinoma (RCC) diagnosis and treatment. In this study, a dramatic decrease of the solute carrier family 47 member 2 (SLC47A2) mRNA in RCC comparing with the paired adjacent nontumor tissues from patients at low Tumor Node Metastasis stage was observed. Thus, patients with SLC47A2 transcriptional repression are susceptible to RCC. Little is known about the regulation mechanism of SLC47A2 We found that it was a bivalent gene that was enriched with both histone H3 lysine 4 trimethylation (H3K4me3) and lysine 27 trimethylation (H3K27me3). Loss of mixed lineage leukemia 1 binding at the gene promoter caused decreased H3K4me3 enrichment and H3K4me3/H3K27me3 ratio, and subsequently repressed the expression of SLC47A2 These two epigenetic markers modulated the expression of SLC47A2 simultaneously, suggesting the regulation pattern for bivalent genes. Histone H3 lysine 27 acetylation also contributed to the expression of SLC47A2 An E2F1-histone deacetylase 10 complex catalyzed deacetylation of H3K27, then prevented the enrichment of H3K4me3, and finally reduced SLC47A2 expression. Consequently, the combined effect of all these factors determined SLC47A2 transcriptional repression in RCC tissues.


Asunto(s)
Carcinoma de Células Renales/metabolismo , Histonas/metabolismo , Neoplasias Renales/metabolismo , Lisina/metabolismo , Proteínas de Transporte de Catión Orgánico/genética , Transcripción Genética , Acetilación , Carcinoma de Células Renales/genética , Línea Celular Tumoral , Inmunoprecipitación de Cromatina , Epigénesis Genética , Células HEK293 , Histonas/genética , Humanos , Neoplasias Renales/genética , Metilación
19.
J Endourol ; 30(11): 1169-1179, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27626367

RESUMEN

INTRODUCTION: The traditional procedure for the management of bilateral ureteral stones is staged ureteroscopic lithotripsy (URS). However, in recent years particularly, some urologists advocate same-session bilateral URS on the ground of success rates and minimal morbidity. This systematic review is to evaluate the efficacy and safety of same-session bilateral ureteroscopy for the treatment of ureteral calculi. MATERIALS AND METHODS: We conducted a bibliographic search using MEDLINE (1980 to August 2015) and EMBASE (1980 to August 2015). Review articles and abstract data were excluded and only studies in English reporting on outcomes of bilateral URS were included in this meta-analysis. Two reviewers independently assessed the quality of each included studies and extracted data. STATA 12.0 was used for meta-analysis. RESULTS: In 11 studies, 431 patients were reportedly treated with bilateral URS. Most of the stone sizes were not larger than 20 mm. The mean stone-free rate is 96% for the distal ureter, 85% for the middle ureter, and 72% for the proximal ureter. The mean operative time ranged from 45 to 100 minutes with an average hospital stay from 2 to 4 days. The overall complications rates were 17%, with the incidence of postoperative fever 4%, postoperative pain 20%, and gross hematuria 4%. Other complications, including urosepsis, urinary tract infection, small mucosal laceration, stone migration, and ureteral perforation, accounted for 6% of overall complications. CONCLUSIONS: This meta-analysis found that bilateral same-session ureteroscopy could achieve a high overall stone-free rate. There might be a relatively higher complication incidence, but most of the complications are minor. For selected cases, bilateral URS could be safe and effective.


Asunto(s)
Litotricia/métodos , Cálculos Ureterales/cirugía , Ureteroscopía/métodos , Anciano , Femenino , Fiebre , Hematuria , Humanos , Incidencia , Tiempo de Internación , Masculino , Persona de Mediana Edad , Tempo Operativo , Dolor Postoperatorio , Seguridad del Paciente , Sepsis , Resultado del Tratamiento , Uréter/cirugía , Cálculos Ureterales/epidemiología , Adulto Joven
20.
World J Surg Oncol ; 14: 74, 2016 Mar 09.
Artículo en Inglés | MEDLINE | ID: mdl-26957001

RESUMEN

BACKGROUND: Diffuse renal and retroperitoneal metastasis of prostatic origin is an uncommon spread pattern of prostate cancer. CASE PRESENTATION: We described a 74-year-old male patient who was admitted because of dysuria and nocturia. Physical examination and imaging study indicated prostate mass, and laboratory analysis revealed elevated prostate specific antigen (PSA). The diagnosis of prostate cancer was established after biopsy. In the further evaluation, diffuse renal and retroperitoneal metastasis of prostate cancer was confirmed. Radiotherapy combined with endocrine therapy was given. CONCLUSIONS: Our present case emphasized that the routine metastatic work-up was quite necessary, since a small proportion of men with advanced prostate cancer might experience metastases in atypical sites.


Asunto(s)
Adenocarcinoma/patología , Neoplasias Renales/secundario , Neoplasias de la Próstata/patología , Neoplasias Retroperitoneales/secundario , Adenocarcinoma/terapia , Anciano , Quimioradioterapia , Humanos , Neoplasias Renales/terapia , Masculino , Clasificación del Tumor , Pronóstico , Neoplasias de la Próstata/terapia , Neoplasias Retroperitoneales/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...